全文获取类型
收费全文 | 1363篇 |
免费 | 81篇 |
国内免费 | 4篇 |
专业分类
耳鼻咽喉 | 25篇 |
儿科学 | 26篇 |
妇产科学 | 28篇 |
基础医学 | 165篇 |
口腔科学 | 32篇 |
临床医学 | 91篇 |
内科学 | 270篇 |
皮肤病学 | 28篇 |
神经病学 | 59篇 |
特种医学 | 28篇 |
外国民族医学 | 1篇 |
外科学 | 366篇 |
综合类 | 17篇 |
一般理论 | 1篇 |
预防医学 | 65篇 |
眼科学 | 42篇 |
药学 | 100篇 |
中国医学 | 7篇 |
肿瘤学 | 97篇 |
出版年
2023年 | 10篇 |
2022年 | 14篇 |
2021年 | 39篇 |
2020年 | 37篇 |
2019年 | 35篇 |
2018年 | 42篇 |
2017年 | 23篇 |
2016年 | 35篇 |
2015年 | 43篇 |
2014年 | 58篇 |
2013年 | 82篇 |
2012年 | 119篇 |
2011年 | 90篇 |
2010年 | 65篇 |
2009年 | 45篇 |
2008年 | 89篇 |
2007年 | 75篇 |
2006年 | 87篇 |
2005年 | 73篇 |
2004年 | 72篇 |
2003年 | 70篇 |
2002年 | 44篇 |
2001年 | 21篇 |
2000年 | 22篇 |
1999年 | 13篇 |
1998年 | 18篇 |
1997年 | 13篇 |
1996年 | 8篇 |
1995年 | 16篇 |
1994年 | 5篇 |
1993年 | 9篇 |
1992年 | 10篇 |
1991年 | 10篇 |
1990年 | 9篇 |
1989年 | 4篇 |
1988年 | 8篇 |
1987年 | 5篇 |
1985年 | 2篇 |
1984年 | 2篇 |
1983年 | 3篇 |
1982年 | 3篇 |
1981年 | 3篇 |
1979年 | 3篇 |
1978年 | 5篇 |
1977年 | 3篇 |
1976年 | 3篇 |
1975年 | 1篇 |
1973年 | 1篇 |
1970年 | 1篇 |
排序方式: 共有1448条查询结果,搜索用时 282 毫秒
91.
92.
93.
94.
95.
Jan IA Jalali M Mirza FM Ali M Saleem N Hussain E 《Journal of the College of Physicians and Surgeons--Pakistan : JCPSP》2004,14(5):300-301
A seven month old male baby presented to emergency room in shock. Patient had 3 hours history of massive fresh bleeding per rectum. Emergency laparotomy revealed Meckel's diverticulum (MD) with large vitello-intestinal artery responsible for massive bleeding. Diverticulectomy was performed. 相似文献
96.
97.
98.
Patterns of uveitis in a tertiary eye care center in Iran 总被引:1,自引:0,他引:1
Soheilian M Heidari K Yazdani S Shahsavari M Ahmadieh H Dehghan M 《Ocular immunology and inflammation》2004,12(4):297-310
PURPOSE: To identify the distribution and characteristics of new uveitis referrals to a tertiary eye care center in Tehran. METHODS: A three-year prospective study was carried out to obtain information on 544 new patients referred with uveitis. A complete ophthalmologic examination was performed in all cases; a routine set of tests and an additional battery of directed workup were conducted when indicated. RESULTS: Mean age was 32.3 years. There was no significant sex predominance. The most common forms of uveitis were anterior (38.4%) vs. other anatomical forms, chronic (62.1%) vs. acute (28.3%), nongranulomatous (85.5%) vs. granulomatous (14.5%), and noninfectious (83.5%) vs. infectious (16.5%). With regard to etiology, 45.5% were idiopathic, 19.9% were due to specific ocular disease, and 37.3% were associated with systemic disorders. Behcet's disease was the most common noninfectious disease and toxoplasmosis the most common infectious entity. The most prevalent causes were idiopathic, Fuchs' heterochromic iridocylitis, and seronegative spondyloarthropathies in anterior uveitis; toxoplasmosis, Eales disease, and toxocariasis in posterior uveitis; idiopathic, sarcoidosis, and multiple sclerosis in intermediate uveitis; and, finally, Behcet's disease, idiopathic, and Vogt-Koyanagi-Harada syndrome in panuveitis. The most frequent cause in patients under 16 years of age was pars planitis. Over 80% of the patients belonged to middle-to-upper socioeconomic classes. Uveitis significantly affected patients' lives in 63.1% of the cases. CONCLUSION: Although the current study was performed at a referral center, it may reflect to some extent the different distribution of uveitis in Iran and probably other Middle Eastern countries. Some entities such as presumed ocular histoplasmosis were not found, cytomegalovirus retinitis and birdshot chorioretinopathy were extremely rare, and HLA-B27-associated iridocyclitis was less commonly observed. In contrast, Behcet's disease, Fuchs' heterochromic iridocyclitis, Eales disease, and toxocariasis were among the more prevalent entities. 相似文献
99.
Tassone P Gozzini A Goldmacher V Shammas MA Whiteman KR Carrasco DR Li C Allam CK Venuta S Anderson KC Munshi NC 《Cancer research》2004,64(13):4629-4636
HuN901 is a humanized monoclonal antibody that binds with high affinity to CD56, the neuronal cell adhesion molecule. HuN901 conjugated with the maytansinoid N(2')-deacetyl-N(2')-(3-mercapto-1-oxopropyl)-maytansine (DM1), a potent antimicrotubular cytotoxic agent, may provide targeted delivery of the drug to CD56 expressing tumors. Based on gene expression profiles of primary multiple myeloma (MM) cells showing expression of CD56 in 10 out of 15 patients (66.6%) and flow cytometric profiles of MM (CD38(bright)CD45(lo)) cells showing CD56 expression in 22 out of 28 patients (79%), we assessed the efficacy of huN901-DM1 for the treatment of MM. We first examined the in vitro cytotoxicity and specificity of huN901-DM1 on a panel of CD56(+) and CD56(-) MM cell lines, as well as a CD56(-) Waldenstrom's macroglobulinemia cell line. HuN901-DM1 treatment selectively decreased survival of CD56(+) MM cell lines and depleted CD56(+) MM cells from mixed cultures with a CD56(-) cell line or adherent bone marrow stromal cells. In vivo antitumor activity of huN901-DM1 was then studied in a tumor xenograft model using a CD56(+) OPM2 human MM cell line in SCID mice. We observed inhibition of serum paraprotein secretion, inhibition of tumor growth, and increase in survival of mice treated with huN901-DM1. Our data therefore demonstrate that huN901-DM1 has significant in vitro and in vivo antimyeloma activity at doses that are well tolerated in a murine model. Taken together, these data provide the framework for clinical trials of this agent to improve patient outcome in MM. 相似文献
100.
Simultaneous integrated boost for breast cancer using IMRT: a radiobiological and treatment planning study 总被引:1,自引:0,他引:1
Guerrero M Li XA Earl MA Sarfaraz M Kiggundu E 《International journal of radiation oncology, biology, physics》2004,59(5):1352-1522
PURPOSE: The purpose of this work is to explore the possibility of using intensity-modulated radiation therapy (IMRT) to deliver the boost dose to the tumor bed simultaneously with the whole-breast IMRT to reduce the radiation treatment time by 1-2 weeks. METHODS AND MATERIALS: The biologically effective dose (BED) for different treatments was calculated using the linear-quadratic (LQ) model with parameters previously derived for breast cancer from clinical data (alpha/beta = 10Gy, alpha = 0.3Gy(-1)). A potential doubling time of 15 days (from in vitro measurements) for breast cancer and a generic alpha/beta ratio of 3 Gy for normal tissues were used. A series of regimens that use IMRT as initial treatment and an IMRT simultaneous integrated boost (SIB) were derived using biologic equivalence to conventional schedules. Possible treatment plans with IMRT SIB to the tumor bed were generated for 2 selected breast patients, 1 with a shallow tumor and 1 with a deep-seated tumor. Plans with a simultaneous integrated electron boost were also generated for comparison. Dosimetric merits of these plans were evaluated based on dose volume histograms. RESULTS: A commonly used conventional treatment of 45 Gy (1.8 Gy x 25) to the whole breast and then a boost of 20 Gy (2 Gy x 10) is biologically equivalent to an alternative plan of 1.8 Gy x 25 to the whole breast with a 2.4 Gy x 25 SIB to the tumor bed. The new regime reduces treatment time from 7 to 5 weeks. For the patient with a deep-seated tumor, the IMRT plans reduce the volume of the breast that receives high doses (compared with the conventional photon boost plan) and provides good coverage of the target volumes. CONCLUSION: It is biologically and dosimetrically feasible to reduce the overall treatment time for breast radiotherapy by using an IMRT simultaneous integrated boost. For selected patient groups, IMRT plans with a new regimen can be equal to or better than conventional plans. 相似文献